Holen Sie sich die Stockscreener-App
18.00
1.75%
-0.32
Vorhandelsmarkt:
18.05
0.05
+0.28%
Schlusskurs vom Vortag:
$18.32
Offen:
$17.625
24-Stunden-Volumen:
1.72M
Relative Volume:
1.31
Marktkapitalisierung:
$1.49B
Einnahmen:
$46.02M
Nettoeinkommen (Verlust:
$-70.80M
KGV:
-9.8901
EPS:
-1.82
Netto-Cashflow:
$-1.61M
1W Leistung:
+1.35%
1M Leistung:
+45.99%
6M Leistung:
+51.52%
1J Leistung:
+196.05%
1-Tages-Spanne:
$17.14
$18.45
1-Wochen-Bereich:
$16.92
$18.87
52-Wochen-Spanne:
$3.91
$19.11
Eyepoint Inc Stock (EYPT) Company Profile
Firmenname
Eyepoint Inc
Sektor
Branche
Telefon
617-926-5000
Adresse
480 PLEASANT STREET, WATERTOWN, MA
Compare EYPT vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EYPT
Eyepoint Inc
|
18.00 | 1.52B | 46.02M | -70.80M | -1.61M | -1.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Eyepoint Inc Stock (EYPT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-17 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2025-01-07 | Eingeleitet | Citigroup | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-08-28 | Eingeleitet | Jefferies | Buy |
| 2024-01-22 | Eingeleitet | JP Morgan | Overweight |
| 2023-11-02 | Eingeleitet | Mizuho | Buy |
| 2023-04-21 | Eingeleitet | Robert W. Baird | Outperform |
| 2022-07-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2021-03-01 | Eingeleitet | Cowen | Outperform |
| 2021-01-28 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-04-06 | Herabstufung | B. Riley FBR | Buy → Neutral |
| 2019-11-04 | Fortgesetzt | Laidlaw | Buy |
| 2019-09-12 | Eingeleitet | Guggenheim | Buy |
Alle ansehen
Eyepoint Inc Aktie (EYPT) Neueste Nachrichten
Chardan Raises Price Target on EyePoint Pharmaceuticals to $29 From $27, Keeps Buy Rating - marketscreener.com
EyePoint (EYPT) Analyst Rating Update: Price Target Increased to $30 | EYPT Stock News - GuruFocus
EyePoint: The 'Pre-Readout' Surge Is Hiding A Commercial Reality Check (NASDAQ:EYPT) - Seeking Alpha
EyePoint (EYPT) Q4 2025 Earnings Call Transcript - The Globe and Mail
Is It Too Late To Consider EyePoint (EYPT) After A 1‑Year Surge And DCF Upside? - simplywall.st
EyePoint: Fourth Quarter Financial Results Overview - Bitget
EyePoint Inc (EYPT) Q4 2025 Earnings Call Highlights: Navigating Revenue Decline Amid Promising Clinical Advances - GuruFocus
Chardan raises EyePoint stock price target to $29 on cash position - Investing.com UK
EYPT (EyePoint) Equity-to-Asset : 0.80 (As of Sep. 2025) - GuruFocus
EYPT (EyePoint) ROE % : -107.10% (As of Sep. 2025) - GuruFocus
Chardan Capital Issues Positive Forecast for Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price - MarketBeat
Chardan Capital Raises Price Target for EYPT to $29.00, Maintains Buy Rating | EYPT Stock News - GuruFocus
Eyepoint Pharmaceuticals (NASDAQ:EYPT) Stock Price Down 4.7%Should You Sell? - MarketBeat
Earnings call transcript: Eyepoint Pharmaceuticals Q4 2025 reveals revenue drop - Investing.com South Africa
EyePoint Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Eyepoint Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
EYPT: DURAVYU's pivotal Phase III trials progress with strong safety, efficacy, and funding into 2027 - TradingView
EYPT: DURAVYU advanced in pivotal trials with strong cash reserves and key data readouts ahead - TradingView
EyePoint Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Eyepoint Pharma earnings missed by $0.06, revenue fell short of estimates - Investing.com Canada
EyePoint, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2025 - marketscreener.com
EyePoint Inc (NASDAQ:EYPT) Stock Falls on Q4 Earnings and Revenue Miss - ChartMill
EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates - Nasdaq
EyePoint Pharmaceuticals' Q4 Net Loss Widens, Revenue Drops - marketscreener.com
Earnings Flash (EYPT) EyePoint Posts Q4 Net Loss $0.81 a Share, vs. FactSet Est of $0.77 Loss - marketscreener.com
Earnings Flash (EYPT) EyePoint, Inc. Reports Q4 Revenue $620,000, vs. FactSet Est of $990,000 - marketscreener.com
EYPT Forecasts Financial Stability Through Key Program Milestones - GuruFocus
EYEPOINT PHARMACEUTICALS ($EYPT) Releases Q4 2025 Earnings - Quiver Quantitative
EyePoint: Q4 Earnings Snapshot - marketscreener.com
EyePoint Reports Fourth Quarter and Full-Year 2025 Financial Results and Highlights Recent Corporate Developments - TradingView
EYPT: DURAVYU Phase 3 trials progress, with strong cash reserves funding operations into Q4 2027 - TradingView
EyePoint (Nasdaq: EYPT) deepens 2025 loss while pushing DURAVYU into Phase 3 - Stock Titan
Earnings Summary: EyePoint Q4 - Benzinga
EyePoint at TD Cowen Conference: DURAVYU’s Market Potential By Investing.com - Investing.com Canada
EYPT: Phase 3 trials advance with unique IL-6 mechanism, targeting a $15B global retina market - TradingView
A Preview Of EyePoint Pharmaceuticals's Earnings - Benzinga
EyePoint Pharmaceuticals to Announce Q4 Earnings on March 4 - Intellectia AI
Eyepoint Pharma earnings up next as pivotal trial data looms By Investing.com - Investing.com Canada
Eyepoint Pharma earnings up next as pivotal trial data looms - Investing.com Nigeria
EyePoint Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Performance Metrics - Markets Mojo
EyePoint begins dosing in phase 3 DME trials for DURAVYU - Eyes On Eyecare
EYPT Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
EyePoint doses first patients in phase 3 DME trials for DURAVYU - Investing.com Australia
Eyepoint Inc topline data for Duravyu in dme anticipated in 2h 2027 - marketscreener.com
Eyepoint Inc Topline Data For Duravyu In Dme Anticipated In 2H 2027 - TradingView
EyePoint Doses First Patients in Phase 3 Trials of Duravyu in Diabetic Macular Edema - marketscreener.com
EyePoint Starts Global Phase 3 Trials for DURAVYU - TipRanks
EyePoint doses first patients in Phase 3 COMO and CAPRI trials for DURAVYU in DME - TradingView
EyePoint (EYPT) doses first patients in DURAVYU Phase 3 DME trials - Stock Titan
Six-month EyePoint eye implant in late-stage tests for diabetic vision loss - Stock Titan
Is EyePoint (EYPT) Recasting Its Ophthalmology Playbook With a Veteran Launch Executive at DURAVYU? - simplywall.st
Finanzdaten der Eyepoint Inc-Aktie (EYPT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):